The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is the most frequent cause of cancer deaths worldwide; nearly half contain mutations in the receptor tyrosine kinase/RAS pathway. Here we show that RAS-pathway mutant NSCLC cells depend on the transcription factor GATA2. Loss of GATA2 reduced the viability of NSCLC cells with RAS-pathway mutations, whereas wild-type cells were unaffected. Integrated gene expression and genome occupancy analyses revealed GATA2 regulation of the proteasome, and IL-1-signaling, and Rho-signaling pathways. These pathways were functionally significant, as reactivation rescued viability after GATA2 depletion. In a Kras-driven NSCLC mouse model, Gata2 loss dramatically reduced tumor development. Furthermore, Gata2 deletion in established Kras mutant tumors induced striking regression. Although GATA2 itself is likely undruggable, combined suppression of GATA2-regulated pathways with clinically approved inhibitors caused marked tumor clearance. Discovery of the nononcogene addiction of KRAS mutant lung cancers to GATA2 presents a network of druggable pathways for therapeutic exploitation.

[1]  S. Camper,et al.  Pituitary-specific Gata2 knockout: effects on gonadotrope and thyrotrope function. , 2006, Molecular endocrinology.

[2]  M. White,et al.  RalB GTPase-Mediated Activation of the IκB Family Kinase TBK1 Couples Innate Immune Signaling to Tumor Cell Survival , 2006, Cell.

[3]  L. Hennighausen,et al.  Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. , 2008, Genes & development.

[4]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[5]  R. Deshaies,et al.  Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. , 2010, Molecular cell.

[6]  W. Hahn,et al.  Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. , 2010, The Journal of clinical investigation.

[7]  M. Barbacid,et al.  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. , 2010, Cancer cell.

[8]  C. Sousa.  Faculty Opinions recommendation of RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. , 2006 .

[9]  Michael D. Wilson,et al.  ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. , 2009, Methods.

[10]  Anna L. Brown,et al.  Heritable GATA2 Mutations Associated with Familial Myelodysplastic Syndrome and Acute Myeloid Leukemia , 2011, Nature Genetics.

[11]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[12]  C. Dinarello.  Why not treat human cancer with interleukin-1 blockade? , 2010, Cancer and Metastasis Reviews.

[13]  Erik Sahai,et al.  Conditional ROCK Activation In vivo Induces Tumor Cell Dissemination and Angiogenesis , 2004, Cancer Research.

[14]  R. DePinho,et al.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.

[15]  Min Jae Lee,et al.  Enhancement of Proteasome Activity by a Small-Molecule Inhibitor of Usp14 , 2010, Nature.

[16]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[17]  G. Courtois,et al.  Complementation Cloning of NEMO, a Component of the IκB Kinase Complex Essential for NF-κB Activation , 1998, Cell.

[18]  D. Tuveson,et al.  C-Raf is required for the initiation of lung cancer by K-Ras(G12D). , 2011, Cancer discovery.

[19]  S. Batzoglou,et al.  Genome-Wide Analysis of Transcription Factor Binding Sites Based on ChIP-Seq Data , 2008, Nature Methods.

[20]  Kwok-Kin Wong,et al.  Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. , 2011, Cancer cell.

[21]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[22]  J. Kench,et al.  A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes , 2009, Oncogene.

[23]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[24]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[25]  Erik Sahai,et al.  ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. , 2011, Cancer cell.

[26]  J. Montero,et al.  Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors , 2011, Clinical Cancer Research.

[27]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[28]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[29]  G. Courtois,et al.  Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. , 1998, Cell.

[30]  W. Ouwehand,et al.  Genome-wide Analysis of Simultaneous GATA1/2, RUNX1, FLI1, and SCL Binding in Megakaryocytes Identifies Hematopoietic Regulators , 2011, Developmental cell.

[31]  R. Adams,et al.  Eph/ephrin molecules--a hub for signaling and endocytosis. , 2010, Genes & development.

[32]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[33]  M. Barbacid,et al.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. , 2011, Cancer cell.

[34]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[35]  Q. Tong,et al.  Function of GATA transcription factors in preadipocyte-adipocyte transition. , 2000, Science.

[36]  J. Lacal,et al.  Activation of the nuclear factor-KB by Rho , CDC 42 , and Rac1 proteins , 2007 .

[37]  Saijuan Chen,et al.  Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia , 2008, Proceedings of the National Academy of Sciences.

[38]  H. Aburatani,et al.  Epigenetically coordinated GATA2 binding is necessary for endothelium‐specific endomucin expression , 2011, The EMBO journal.

[39]  Henriette O'Geen,et al.  Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. , 2009, Molecular cell.

[40]  D. Feldser,et al.  Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma , 2009, Nature.

[41]  Fiona M. Watt,et al.  Nanog maintains pluripotency of mouse embryonic stem cells by inhibiting NFκB and cooperating with Stat3 , 2008, Nature Cell Biology.

[42]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[43]  Jos Jonkers,et al.  Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. , 2007, Physiological genomics.

[44]  G. Stamp,et al.  Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice , 2007, Cell.

[45]  G. Evan,et al.  Modelling Myc inhibition as a cancer therapy , 2008, Nature.

[46]  Stuart H. Orkin,et al.  An early haematopoietic defect in mice lacking the transcription factor GATA-2 , 1994, Nature.

[47]  G. Stamp,et al.  RalGDS is required for tumor formation in a model of skin carcinogenesis. , 2005, Cancer cell.

[48]  Emery H. Bresnick,et al.  Genetic framework for GATA factor function in vascular biology , 2011, Proceedings of the National Academy of Sciences.

[49]  I. Screpanti,et al.  Proapoptotic function of the retinoblastoma tumor suppressor protein. , 2009, Cancer cell.

[50]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Feldser,et al.  Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. , 2011, Cancer discovery.

[52]  Charles Elkan,et al.  Fitting a Mixture Model By Expectation Maximization To Discover Motifs In Biopolymer , 1994, ISMB.

[53]  L. O’Neill,et al.  The interleukin‐1 receptor/Toll‐like receptor superfamily: 10 years of progress , 2008, Immunological reviews.

[54]  C. Marshall,et al.  Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1 , 1998, Nature.

[55]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[56]  O. Bernard,et al.  Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway , 2001, Oncogene.

[57]  Zhaodan Cao,et al.  TRAF6 is a signal transducer for interleukin-1 , 1996, Nature.

[58]  R. Treisman,et al.  Transformation mediated by RhoA requires activity of ROCK kinases , 1999, Current Biology.

[59]  R. Bravo,et al.  Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. , 1997, Genes & development.

[60]  Sahar Mansour,et al.  Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome) , 2011, Nature Genetics.